临床医生与患者因素与接受先进治疗类风湿关节炎患者长期使用糖皮质激素相关
该研究在CorEvitas类风湿关节炎登记中嵌套临床医生调查,分析启动新生物制剂或JAK抑制剂后6个月仍使用糖皮质激素的患者和医生因素。结果显示,疾病活动度高、年龄≤45或>75岁、病程长、既往生物制剂/JAKi多、肺病及较早日历年份与更多GC使用相关;医生对泼尼松≤5 mg/日、生物制剂或JAKi安全性担忧较低均与更多GC处方相关。
要点
- 患者因素中高疾病活动度、极端年龄、长病程、多既往先进治疗及肺病与6个月GC使用增加相关。
- 医生对泼尼松≤5 mg/日担忧较低者6个月GC处方增加(aOR 1.98,95%CI 1.17-3.36)。
- 医生对生物制剂或JAKi担忧较低亦与更多GC处方相关,提示广泛的风险获益态度影响处方。
核心结论
- 医生对GC、生物制剂和JAKi安全性的担忧较低均与更多GC处方相关,提示广泛的风险获益优先态度而非仅GC特定担忧驱动GC使用。
研究设计与样本
- 在CorEvitas类风湿关节炎登记中嵌套临床医生调查,2023至2024年调查256名活跃医生,92名(36%)应答,其中81名医生对应3,966名合格患者,164名未应答医生对应3,196名合格患者。
- 识别启动新生物制剂或JAK抑制剂(JAKi)的RA患者,采用混合效应逻辑回归模型评估6个月时GC使用相关的患者因素,并调整患者因素后评估医生因素。
主要发现
- 6个月时GC使用增加与更高疾病活动度、年龄≤45或>75岁、更长病程、更多既往生物制剂/JAKi、肺病及较早日历年份相关。
- 对泼尼松≤5 mg/日担忧较少的医生更可能在6个月时处方GC(aOR 1.98,95%CI 1.17-3.36)。
- 对生物制剂担忧较少的医生aOR 2.47(95%CI 1.33-4.49),对JAKi担忧较少的医生aOR 2.35(95%CI 1.31-4.22),均与更多GC处方相关。
关键数值与推荐
- 医生对泼尼松≤5 mg/日担忧较少与6个月GC处方相关aOR 1.98(95%CI 1.17-3.36)。
- 医生对生物制剂担忧较少与6个月GC处方相关aOR 2.47(95%CI 1.33-4.49)。
- 医生对JAKi担忧较少与6个月GC处方相关aOR 2.35(95%CI 1.31-4.22)。
临床怎么用
- 临床中应关注医生对治疗风险获益的广泛态度,而不仅限于GC特定担忧,以优化RA患者的GC处方行为。
- 对高疾病活动度、极端年龄、长病程、多既往先进治疗及合并肺病的RA患者,应加强GC使用监测与管理。
局限性
- 医生调查应答率为36%,可能存在应答偏倚。
- 研究为观察性设计,无法确定因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Despite guideline recommendations, long-term glucocorticoid (GC) use is common in rheumatoid arthritis (RA). We conducted a clinician survey nested within a large registry to identify patient and clinician factors associated with GC use. METHODS: Clinicians contributing patients to the CorEvitas Rheumatoid Arthritis Registry were surveyed between 2023 and 2024, capturing demographics, medication safety concerns, and a range of other attitudes. We then identified patients with RA initiating a new biologic or JAK inhibitor (JAKi). Patient factors associated with GC use six months after treatment initiation were assessed with a mixed-effects logistic regression model. Similar models assessed clinician factors associated with GC use at six months, adjusting for patient factors. RESULTS: Among 256 active clinicians, 92 (36%) responded to the survey, of which 81 had 3,966 qualifying patients, whereas 164 nonresponders had 3,196 qualifying patients. Higher disease activity, age ≤45 or >75 years, longer disease duration, more previous biologics/JAKi, lung disease, and earlier calendar year were associated with greater GC use at six months. Clinicians with less concern about prednisone ≤5 mg/day were more likely to prescribe GCs at six months (adjusted odds ratio [aOR] 1.98, confidence interval [CI] 1.17-3.36), but similar or stronger associations were seen for clinicians with less concern about biologics (aOR 2.47, 95% CI 1.33-4.49) or JAKi (aOR 2.35, 95% CI 1.31-4.22). CONCLUSION: Lower clinician concerns about GC, biologic, and JAKi safety were associated with greater GC prescribing, suggesting that broad attitudes toward prioritizing treatment benefits versus risks (rather than just specific GC concerns) may drive GC prescribing, with important implications for clinician education.
引用
- George MD, Reed G, Kearney MD, et al. Clinician and Patient Factors Associated With Long-Term Glucocorticoid Use in People With Rheumatoid Arthritis Receiving Advanced Therapies. Arthritis Care Res (Hoboken). 2026. PMID: 42482401. doi:10.1002/acr.80119
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。